Severe atopic dermatitis/eczema - a review of the literature

Current Allergy and Clinical Immunology

Volumn 25, Issue 3, 2012, Pages 140-144

  Gouws, Annemarie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; CALCIUM; CHLORHEXIDINE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DOCOSAHEXAENOIC ACID; FLUCLOXACILLIN; FLUNISOLIDE; FUSIDIC ACID; GAMMA INTERFERON; GLUCOCORTICOID; HERBACEOUS AGENT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOMYCIN; PREDNISOLONE; PSEUDOMONIC ACID; PSORALEN; VITAMIN D;

ABDOMINAL PAIN; ACALCULOUS CHOLECYSTITIS; ADRENAL INSUFFICIENCY; ALLERGIC REACTION; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; ATOPIC KERATOCONJUNCTIVITIS; AVASCULAR NECROSIS; BACTERIAL SUPERINFECTION; BASAL CELL CARCINOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARCINOGENESIS; CATARACT; COMORBIDITY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; EARLY DIAGNOSIS; ERYTHRODERMA; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; GROWTH RETARDATION; HEMATURIA; HEPATITIS; HERPES SIMPLEX; HIP AVASCULAR NECROSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFECTION SENSITIVITY; KAPOSI VARICELLIFORM ERUPTION; KERATOCONUS; KIDNEY FUNCTION; LIVER TOXICITY; LUNG FIBROSIS; LYMPHOCYTOPENIA; LYMPHOMA; MENTAL STRESS; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PHOTOTHERAPY; PREVALENCE; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RETINA DETACHMENT; RETINITIS; REVIEW; SECONDARY INFECTION; SEIZURE; SERUM SICKNESS; SEVERE ATOPIC DERMATITIS ECZEMA; SIDE EFFECT; SKIN CANCER; SKIN SENSITIZATION; SOCIAL PSYCHOLOGY; SOUTH AFRICA; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; STAPHYLOCOCCUS INFECTION; SUPERINFECTION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VIRAL SUPERINFECTION; VIRUS INFECTION;

EID: 84872354310     PISSN: 16093607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Sinclair W, Aboobaker J, Jordaan F, Modi M, Todd G. Management of atopic dermatitis in adolescents and adults in South Africa. S Afr Med J 2008;98(4):303-320.
2. National Institute for Health and Clinical Excellence (NICE) clinical guideline No. 57: Management of atopic eczema in children from birth up to the age of 12 years. December 2007. www.nice.org.uk/CG057 (accessed 24 February 2012).
3. Hanifin J. Systemic therapy of atopic dermatitis in children. Program and abstracts of the Society for Pediatric Dermatology Annual Meeting, 12-15 July 2007, Chicago, Illinois.
4. Williams HC. Atopic dermatitis. N Engl J Med 2005;352:2314-2324.
5. Spergel JM, Dellavale RP, Levy ML, Fowler J, Corona R. Management of severe refractory atopic dermatitis (eczema). Literature review current through Feb 2012. www.uptodate.com (accessed 28 March 2012).
6. Emmerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998;139:73-76.
7. Dotterud LK, Kvammen B, Lund E, Falk ES. Prevalence and some clinical aspects of atopic dermatitis in the community of Sor-Vanger. Acta Derm Venereol 1995;75:50-53.
8. Zeppa L, Bellini V, Lisi P. Atopic dermatitis in adults. Dermatitis 2011;22(1):40-46.
9. Sandstrom FMH, Faergemann J. Atopic dermatitis in adults: does it disappear with age? Acta Derm Venereol 2006;86:135-139.
10. Odhiambo JA, Williams HC, Clayton DO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009; 124(6):1251-1258.
11. Ben-Gashir MA, Seed PT, Hay RJ. Predictors of atopic dermatitis severity over time. J Am Acad Dermatol 2004;50(3):349-356.
12. Peterson JD, Chan LS. A comprehensive management guide for atopic dermatitis. Dermatology Nursing 2006;18(6):531-542.
13. Harper J, Oranje AP, Prose NS. Textbook of Paediatric Dermatology, Vol 2. 2nd ed. Massachusetts: Blackwell, 2006: 237-238.
14. Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol 2011;7(1). www.aacijournal.com (accessed 20 February 2012).
15. Ricci G, Patrizi A, Gianetti A, Dondi A, Bendandi B, Masi M. Does improved management of atopic dermatitis influence the appearance of respiratory allergic diseases? A follow-up study. Clin Mol Allergy 2010(8). www.clinicalmolecularallergy.com/content/8/1/8 (accessed 2 February 2012).
16. Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol 2008;9(4):233-234.
17. Leonard SA. Food allergy: what you need to know. Medscape Allergy & Immunology www.medscape.com/viewarticle/732184 (accessed 6 April 2012).
18. Hon KLE, Wang SS, Leung T. The atopic march: from skin to the airways. Iran J Allergy Immunol 2012;11(1):73-77.
19. Jordaan HF, Visser WI. The diagnosis and management of atopic dermatitis. SAFPJ 2009;51(5): 369-374.
20. Treadwell PA. Eczema and infection. Pediatr Infect Dis J 2008; 27(6):551-552.
21. Werfel T. Bacterial infection and atopic dermatitis. World Allergy Forum www.worldallergy.org/educational_programs/world_allergy_forum/neworleans/werfel.php (accessed 28 February 2012).
22. Cunha BA. Antibiotic Essentials. 10th ed. New York: Physicians Press, 2011.
23. Ravenscroft JC, Layton AM, Eady EA, et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003;148(5):1010-1017.
24. Stanway A. Complications of atopic dermatitis. www.dermnetnz. org (accessed 12 March 2012).
25. Green RJ, Motala C, Potter PC. ALLSA Handbook of Practical Allergy. Cape Town: ALLSA, 2010.
26. Chang-Godinich A, Raizman MB, Lawton AW, Law SK, Rapuano CJ, Roy H. Atopic keratoconjunctivitis. Medscape www.emedicine. medscape.com/article/1194480 (accessed 4 March 2012.
27. Bawazeer AM, Hodge WG, Lorimer B. Atopy and keratoconus: a multivariate analysis. Br J Ophthalmol 2000;84:834-836.
28. Sehgal VN, Jain S. Atopic dermatitis: ocular changes. Int J Dermatol 1994;33(1):11-15.
29. Dhar S, Mondal B, Malakar R, Ghosh A, Gupta AB. Correlation of the severity of atopic dermatitis with growth retardation in paediatric age group. Indian Journal of Dermatology 2005;50(3):125-128.
30. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. American Journal of Clinical Dermatology 2002;3(3):141-147.
31. Kubetin SK. Beware of adrenal suppression when using topical steroids for eczema: asymptomatic side effect to treatment. Paediatric News, 2003. http://findarticles.com/p/articles/mi_hb4384/is_12_37/ai_n29055945 (accessed 4 April 2012).
32. Zollner EW. Inhaled corticosteroids and hypothalamic-pituitaryadrenal axis suppression. SAPR 2009;6(2):12-20.
33. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006;60(8):984-992.
34. Schmitt J. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA 2009;301(7):724-726.
35. Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatology Online Journal 2003;9(2):1.
36. Ring J, Przybilla B, Ruzicka T. Handbook of Atopic Eczema. Berlin: Springer-Verlag, 2006.
37. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.
38. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 2007;87:100-111.
39. Rossiter D, Blockman M, Barnes KI, et al. South African Medicines Formulary. Cape Town: Health and Medical Publishing Group, 2010.
40. Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clinical, Cosmetic and Investigational Dermatology 2010;3:99-117.
41. Nahm DH, Kim ME. Treatment of severe atopic dermatitis with a combination of subcutaneous allergen immunotherapy and cyclosporin. Yonsei Med J 2012;53(1):158-163.
42. Meggitt SJ, Anstey AV, Mustapa MFM, Reynolds NJ, Wakeling S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011;165:711-734.
43. Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011;128:353.
44. Koch C, Dölle S, Metzger M, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008;158(4):786-792.
45. Amestejani M, Salehi BS, Vasigh M, et al. Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. J Drugs Dermatol 2012;11(3):327-330.
46. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema: an intervention review: The Cochrane Skin Group. Assessed as up-to-date: 8 July 2010, Published online on 15 February 2012; www.thecochranelibrary. com (accessed on 10 April 2012).